Novel Laser and Emerging Therapies Show Promise in Acne and Rosacea Treatment
Key Insights
A novel 1726 nm laser shows promise by directly targeting and destroying the sebaceous gland, leading to an 80% reduction in inflammatory acne (search) lesions after 52 weeks.
A triple combination topical cream containing clindamycin, benzoyl peroxide, and adapalene has demonstrated around 50% clearance rates in acne (search) patients.
DFD-29, a low-dose minocycline tablet, shows potential as a new agent for papulopustular rosacea (search), with significant improvements compared to placebo and low-dose doxycycline.
Advancements in acne (search) and rosacea (search) treatments are offering new hope for patients, with innovative laser technologies and emerging topical and oral therapies showing promising results. Emmy Graber, MD, MBA, recently shared insights on these developments at the Fall Clinical Dermatology Conference, highlighting the potential of new 1726 nanometer lasers, combination topicals, and a novel low-dose minocycline for rosacea.
Targeting Sebum Directly with 1726 nm Lasers
Traditional acne (search) treatments have often struggled to directly address sebum production, a key factor in the development of acne. The new 1726 nanometer lasers offer a targeted approach by selectively destroying the sebaceous gland while preserving the integrity of the epidermis. According to Dr. Graber, clinical studies have demonstrated a median reduction of 80% in inflammatory lesions 52 weeks after treatment with this laser, without the need for additional topical or oral agents. This represents a significant advancement, as it directly targets one of the root causes of acne.
Triple Combination Topical Cream for Acne
In 2023, the FDA approved a new triple combination topical cream containing clindamycin, benzoyl peroxide, and adapalene, which became commercially available in 2024. Clinical studies have shown that approximately 50% of patients using this single prescription topical achieved clear or almost clear skin. This combination approach simplifies treatment for patients by delivering three active ingredients in one product, potentially improving adherence and outcomes.
DFD-29: A Potential New Oral Agent for Rosacea
Looking ahead to potential advancements in rosacea (search) treatment, DFD-29 (low-dose minocycline 40mg) is being investigated for papulopustular rosacea. Data suggests that once-daily administration of this oral agent for 16 weeks leads to significant improvements compared to both placebo and low-dose doxycycline (40mg once daily). If approved, this minocycline formulation could represent the first new agent for rosacea in many years, addressing an unmet need in the treatment of this common skin condition.
Addressing Erythema in Rosacea
Dr. Graber also emphasized the importance of addressing erythema, or persistent redness, in rosacea (search) patients. The use of pulsed dye lasers or intense pulsed light (IPL) devices can effectively reduce erythema, leading to significant improvements in patients' quality of life. This highlights the importance of a comprehensive approach to rosacea treatment that addresses all aspects of the condition.